UK markets open in 3 hours 55 minutes

Orphazyme A/S (ORPH)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
16.21+6.16 (+61.29%)
At close: 4:00PM EDT
16.14 -0.07 (-0.43%)
After hours: 07:59PM EDT

Orphazyme A/S

Ole MaalOees Vej 3
Copenhagen 2200
45 39 17 82 72

Full-time employees141

Key executives

NameTitlePayExercisedYear born
Mr. Anders Fink Vadsholt M.B.A., M.Sc., MBAChief Financial Officer944.76kN/A1969
Mr. Christophe Bourdon M.B.A.Chief Exec. OfficerN/AN/A1970
Dr. Thomas Kirkegaard Jensen Ph.D.Co-Founder & Chief Scientific OfficerN/AN/A1977
Ms. Molly PoarchHead of Global CommunicationsN/AN/AN/A
Dr. Thomas BlaettlerChief Medical OfficerN/AN/A1967
Ms. Molly PainterPres of US OrphazymeN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Corporate governance

Orphazyme A/S’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.